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Patient-administered sequential spirometry in healthy 
volunteers and patients with a,-antitrypsin deficiency 
F. MADSEN?, C. S. ULRIK*, A. DIRKSEN *, K. K. HANSEN*, N. H. NIELSEN*, L. FREILUND*, 
K. VISKUM* AND A. KOK-JENSEN* 
*Department of Pulmonary Medicine, Bispebjerg Hospital, and TDepartment of Pulmonary Medicine, 
RHIMA-Centre, Rigshospitalet, Copenhagen, Denmark 
The launching of cheap, pocket-sized spirometers, with data storage capability, has made patient-administered 
sequential spirometry (PASS) an attractive method of monitoring ventilatory capacity. At present, little 
information is available on the quality of PASS, compared to laboratory spirometry. The aim of this study 
was to investigate whether patients could perform PASS without loss of reliability and reproducibility as 
compared with traditional laboratory spirometry. 
Ten healthy volunteers performed spirometry for 1 month and 10 emphysematous patients with ai- 
antitrypsin deficiency (type PiZ) performed spirometry twice daily for up to 2 yr. To fulfil Good Clinical 
Practice criteria on full data documentation, a traditional direct recording spirometer, the Vitalograph 
R-model, was used. A decompression device was used for calibration and a 3.8% annual drift in volume 
registration was noted. This drift was largest for the first year. 
After training, all patients were able to perform unsupervised spirometry, producing technically correct 
forced expiratory curves. Reproducibility of FEV, and FVC obtained by PASS was found to be as good as 
for laboratory spirometry. 
After adjustment for the diurnal variation, the residual variation of FEV, was 2.5% (range 164.2%) for 
healthy volunteers and 5.6% (range 4.2-7.7%) for emphysematous patients. Forced vital capacity showed the 
same pattern. 
In conclusion, PASS is possible in highly motivated individuals without loss of reliability and 
reproducibility when compared to laboratory spirometry. 
Introduction 
Dynamic spirometry of acceptable quality has been 
restricted to laboratories until recently. With the 
introduction of small, pocket-sized spirometers, 
patient-administered sequential spirometry (PASS) 
has become an interesting alternative to labora- 
tory spirometry. However, before PASS is used for 
clinical evaluation of patients and research, both the 
equipment and methods should be standardized. A 
tremendous amount of work has been put into the 
standardization of laboratory spirometry by individ- 
ual researchers as well as by national and inter- 
national scientific societies (l-l 1). This work has 
Received 12 June 1995 and accepted 14 June 1995. 
TAutha to whom correspondence should be addressed at: RHIMA- 
Centre Rigshospitalet, Sektion 7551, Tagensvej 20, DK-2200 
Copenhagen N, Denmark. 
resulted in detailed specifications for equipment and 
testing procedure leading to highly accurate and 
reproducible results. At present, it seems unlikely 
that equipment and testing protocols for laboratory 
spirometry will improve much in the near future. 
In contrast to laboratory spirometry, knowledge 
about the possibilities and limitations of PASS is just 
emerging. Patient-administered sequential spirometry 
has been successfully used in the monitoring of 
lung transplants (12,13), but no information on the 
reliability of PASS was available until recently (14). 
As part of a European controlled clinical trial of 
a,-antitrypsin augmentation therapy (15) it has been 
essential to initiate a standardization process for 
PASS. In 1989, when this study was designed, very 
little information was available on patient perform- 
ance during unsupervised forced expiratory ma- 
noeuvres (16) and furthermore the stability of the 
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Table I Subject characteristics and pulmonary function 
variables 
Healthy 
volunteers 
Mean SD 
q-antitrypsin- 
deficient patients 
Mean SD 
Age (years) 40.8 9.48 41.1 10.0 
Height (m) 1.81 0.10 1.72 0.06 
FEV, (1) 4.31 0.64 1.66 0.48 
FVC (1) 519 0.87 4.50 1.35 
FEV,% pred. (“!) 108.0 12.1 51.5 11.4 
pocket-sized spirometers was virtually unknown. 
Therefore, it was essential that both methods and 
spirometers used for PASS were tested scientifically, 
as has been the case for commercial spirometers used 
in laboratories (17). Today the main interest on 
PASS equipment focuses on hand-held, pocket-sized 
spirometers, but it has only recently become possible 
to collect data which makes a judgement of the 
quality of the expiratory manoeuvre possible. 
Before accepting results obtained with a pocket- 
sized spirometer, documentation of the patients’ 
ability to perform correct forced expiratory ma- 
noeuvres unsupervised, as well as data on short- and 
long-term stability of the equipment, is needed. In 
1991, no pocket-sized spirometers met these demands 
(12, 13, 18, 19). Consequently, instead of using this 
type of spirometer in a long-term clinical trial (15), a 
well-tried, direct writing, wedge spirometer was used 
in this study in order to assure the quality of PASS, 
and thereby fulfil Good Clinical Practice (GCP) 
criteria on data documentation (20). The aim of the 
present study was to investigate whether PASS could 
be performed unsupervised: 
(1) with correct expiratory technique; and 
(2) without loss of reliability and reproducibility 
compared to laboratory spirometry. 
Material and Methods 
STUDY POPULATION 
The study population consisted of 10 healthy sub- 
jects and 10 patients with severe a,-antitrypsin defi- 
ciency (phenotype PiZ) and moderate emphysema 
[35% <FEV, ~60% predicted (3)]. The healthy vol- 
unteers were selected, for a pilot study, from among 
the investigators and their relatives, provided they 
were not smokers. The emphysematous patients par- 
ticipated in a randomized trial of augmentation 
therapy with a,-antitrypsin (Prolastin@ vs. placebo) 
(15). Anthropometric data are given in Table 1. All 
subjects gave informed consent and the study was 
approved by the local Ethics Committee. 
SPIROMETRY 
Ten new VitalographO R models, a direct 
writing, 7 1, dry wedge spirometer (Vitalograph Ltd, 
Buckingham, U.K.), were modified by shunting out 
the start button, thus making spirometry possible 
without manual manoeuvres. This study required 
the ability to simultaneously control and adjust the 
patients’ expiratory techniques, and to blind 
the individual spirometry results, to ensure that the 
patients’ expiratory efforts and number of trials 
would not be affected by prior results. To obtain this 
blinding, charts without pre-printed grids were pro- 
duced. The participants were carefully instructed in 
spirometry for about 1 h and they received written 
information on how to perform spirometry at home. 
They were instructed not to place the spirometers in 
direct sunlight, or near a heater. Spirometry was to 
be performed every morning and evening. A measur- 
ing sequence included at least three maximal forced 
expiratory manoeuvres from total lung capacity 
(TLC) to residual volume (RV), with all timed- 
volume curves of a sequence on one chart. The results 
reported were the greatest FEV, and FVC values 
achieved from at least three technically acceptable 
manoeuvres irrespective of the manoeuvre in which 
they occur. For FEV, and FVC to be considered 
technically acceptable, the test had to be performed 
correctly (inspection of curve and time to peak flow 
~300 ms) and the chosen values should not exceed 
the next highest by more than 5% or 0.11, whichever 
is the greater (21). This was controlled by simple 
inspection by the chart reader. If possible, the 
patients had to continue registration beyond the end 
of the time registration (the maximal registration 
time is 6 s for the Vitalograph R model with standard 
sledge). Subject initials, date, time and room tem- 
perature were noted on the chart. After a maximum 
period of 1 month, all patients were able to produce 
technically perfect spirograms. 
CALIBRATION OF SPIROMETERS 
Calibrations were made every 3 months. The 
calibration procedure of this study consisted of 
volume control by means of a 1 1 syringe with two 
one-way valves (Vitalograph, Buckingham, U.K.), 
and a 3 1 syringe (Hewlett Packard) without valves. A 
decompression device, the ‘calibrator’ (Fig. l), previ- 
ously described in detail (22) was used for dynamic 
calibration. Briefly, it consists of two serially con- 
nected 4 1 constant volume perspex cylinders. These 
are inflated by compressed dry atmospheric air to a 
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Fig. I The decompression flow and volume calibrator. The outlet of the ‘calibrator’ is closed by elevating the piston. The 
calibrator is then inflated to a fraction of the atmospheric pressure, and decompressed by releasing the piston. 
constant fraction above the actual barometric press- 
ure, and then decompressed by an opening mechanism 
driven by gravity. Due to the conical outlet, the piston 
and the bore of the outlet, the resulting flow as a 
function of volume comes close to the normal, human- 
timed, maximal flow-volume relation. By this simple 
construction, the variables determining the timed 
flow-volume relation are reduced to cylinder volume, 
gravity, inflation pressure and characteristics of the 
outlet and opening mechanism. Therefore, the accu- 
racy of differential and atmospheric pressure measure- 
ment, airtightness, lubrication of the piston and 
skill of the operator are critical for the stability of 
this system. To control these factors, a differential 
manometer (NUOVA FIMA@, accuracy f 0.25%, 
smallest interval 0.01 Bar) was used to pre-set inflation 
pressure, and the manometer was calibrated against a 
mercury column every 3 months. One operator per- 
formed 90% of all calibrations. All calibrations 
were done in triplicate. The bellows and tubes of the 
Vitalographs were tested for leaks by inflating the 
bellow and sealing the mouthpiece for 6 h. 
DESIGN 
The study was performed in two sequences. Begin- 
ning in November-December 1990, the healthy 
volunteers performed PASS for 1 month. Repeat- 
ability, which is part of reproducibility (23) was 
tested separately by the healthy volunteers, who 
performed 10 measurements, i.e. 30 complete maxi- 
mal forced expiratory manoeuvres, in one sequence 
only allowing time for physical recovery. In January 
1991, the spirometers were allocated to the patients 
and the clinical trial of a,-antitrypsin augmentation 
therapy was started. Once a week, the patients 
returned the registration charts by post; and once a 
month, the patients were re-instructed in spirometry 
if necessary. The spirometry quality assurance 
included control of calibrator manometer and fit- 
tings, calibration of spirometers, and control of chart 
readers. 
READING OF CHARTS 
Four chart readers were tested before the trial and 
the best was selected for participation. As a test of 
reproducibility of the readers, 30 charts were read 
twice in random order by each reader. The selected 
reader was retested once every year. 
The combined precision of the readers and spirom- 
eters was tested with volume-time curves produced 
by the ‘calibrator’, and results obtained from blank 
charts compared to the results obtained from the 
standard pre-printed charts. The curves drawn on 
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Table 2 Results obtained by four chart readers 
Time Reader 
WI no. 
Lung 
function 
measurement 
Blank registration charts 
compared to lineated charts 
Mean 95% confidence 
difference interval P value 
(ml) G-4 (f-test) 
Blank charts read twice 
Mean 95% confidence 
difference interval P value 
(ml) (ml) (t-test) 
1990 1 FEV, 19 -6 41 0.130 0 -4-3 0,083 
1990 1 FVC -8 -233 7 0.290 -1 -4-2 0.410 
1990 2 FEV, 19 4- 34 0.017 - 24 - 58-10 0.410 
1990 2 FVC 56 - 27-140 0.170 - 12 - 90-69 0.770 
1990 3 FEV, -48 - 213-117 0.540 2 -3- 6 0,430 
1990 3 FVC 29 14 45 0.002 2 -l- 5 0.260 
1990 4 FEV, 23 4 43 0.023 13 12-25 0.032 
1990 4 FVC 38 16 59 0.005 18 8-27 0.001 
1991 1 FEV, 7 2-11 0.005 
1991 1 FVC -2 -5- 1 0.110 
1992 1 FEV, 7 2-13 0.017 
1992 1 FVC -1 -42 0.650 
Thirteen identical timed volume curves were produced by the decompression calibrator on both blank and lineated charts. 
The two sets of charts were read by four readers (14). Thirty expiratory timed volume curves were drawn on blank charts 
and read twice by four readers. These 30 charts were then read annually by one reader. 
blank charts were read with a transparent version of 
the standard chart divided into 1.345 mm/O.05 1 
BTPS subdivisions. Patients recordings are reported 
at BTPS. 
The readers were instructed to check the timed 
volume curves for errors in expiratory technique, for 
repeatability and placement of recording stylus. The 
recorded triggering volume was also checked, and 
if larger than the standard 50 ml recommended for 
the Vitalograph, back extrapolation was performed 
(21). 
STATISTICS 
Standard methods were applied for calculation of 
repeatability and reproducibility (24,25). The yearly 
drift of the spirometers in volume registration was 
defined as the yearly change in percent, and deter- 
mined by linear regression of all calibration volumes 
on time, For PASS, diurnal variation was defined as 
the difference between evening and morning measure- 
ments and calculated by linear regression of FEV, 
and FVC on time (yr) and time of day (dichotomous 
variable: morning= 1, evening=2). 
Results 
READERS AND REGISTRATION CHARTS 
The performance of the four readers and the 
influence of chart type is reported in Table 2. Reader 
no. 1 was selected for further participation in the 
clinical trial. 
CALIBRATION 
A total of 67 calibrations were performed during 
2 yr (one calibration was defined as all syringe and 
‘calibrator’ measurements performed on the same 
spirometer within 1 day). The individual calibration 
results for each spirometer and each date (all vol- 
umes) are presented in Fig. 2, which shows a general 
drift towards larger readings. The drift was largest 
during the first year of the study. The overall regres- 
sion line (thick solid) has a slope of 3.8% yearly (95% 
confidence interval 3.14.Y~). Moreover, it appears 
from Fig. 2 that calibrations were more unevenly 
spaced than planned. Therefore, it was decided to 
lump together calibrations in four groups: (1) initial 
calibrations (November-December 1990); (2) first 
year calibrations (January-October 1991); (3) second 
year calibrations (November 1991-September 1992); 
and (4) final calibrations (after October 1992). For 
each group, the mean date of calibration and the 
mean observed volume from 1 to 6 1 were calculated. 
The results are presented in Fig. 3 which shows that 
the drift towards larger values increased slightly with 
increasing volume. 
REPEATABILITY AND REPRODUCIBILITY OF PASS IN 
HEALTHY VOLUNTEERS AND PATIENTS WITH 
a,-ANTITRYPSIN DEFICIENCY 
Results from 10 measurements within 2 h, and 1 
month PASS in healthy volunteers are reported in 
Table 3. The variations were reasonably small, as 
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Fig. 2 Calibration of 10 Vitalographs@. All recordings 
were divided by the expected volume, and the mean of all 
calibration volumes (l-6 1) from the same calibration 
sequence are plotted over time for each Vitalograph. The 
least square regression line (thick solid) for all Vitalographs 
is also shown. 
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Fig. 3 Calibration of all Vitalographs@. All recordings 
were divided by the expected volume, and the mean of l-6 1 
calibrations for all Vitalographs are plotted over time. The 
majority of calibrations were performed before the study, 
after 200 and 400 days, and after the study. Therefore, the 
mean of all observations in these intervals were used for 
calculations. The volume drift was 3.8% yr - I. -, 11; 
---,21;““,31;~-~,41;-~~--,5~1. 
were the diurnal variations except in one case (no. 5) 
who performed approximately 5% better in the 
morning (4.8% for FEV, and 59% for FVC). 
Patient compliance of twice-daily measurements 
was high. After training, the time spent by the 
patients on spirometry was comparable to the time 
they spent on toothbrushing each morning and 
evening, i.e. approximately 5 min. 
Variations of 2 yr PASS are given in Table 4. 
Approximately one-half of the emphysema patients 
had diurnal variations larger than 5% with low 
morning values. After adjustment for the diurnal 
variations, the residual standard deviations were 4.2- 
7.7% for FEV, and even less (3.3-6.9%) for FVC. 
Discussion 
This study has shown that PASS is possible in 
highly motivated patients. Patients can perform tech- 
nically correct forced expiratory manoeuvres without 
supervision, and there is no loss in reliability when 
PASS is compared to laboratory spirometry. 
In order to meet Good Clinical Practice criteria, 
well-tried equipment in a rather laborious set-up was 
used until sufficient documentation was obtained for 
the reliability of PASS performed with pocket-sized, 
flow-volume recording spirometers (14,16,26). It was 
essential, for patient education, to inspect the curves 
on the spirometric charts, and correct their perform- 
ance if necessary. The partial blinding of spirometric 
results by the use of charts without pre-printed 
grids (blank charts) was a convenient way to avoid 
the possibility of individuals keeping their results 
artificially constant by comparing measurements. 
The equipment, including the calibrator, was 
robust and reliable. The Vitalograph R model toler- 
ated frequent transportation without major prob- 
lems. All 10 Vitalograph’s showed a uniform pattern 
of volume drift towards larger recordings (Figs 2, 3). 
The reasons for this drift are not known. All 10 
spirometers were brand new, and the observation 
that the volume drift was larger during the first year 
than thereafter, may indicate changes in the elastic 
properties of the bellows or the settling of other parts 
of the spirometers. 
A mean drift of 3.8% yr - ’ may have important 
clinical implications, since this change may be similar 
to the therapeutic effect looked for, as in the clinical 
study of a,-antitrypsin augmentation therapy (15). 
Based on the calibration results in this study, the 
authors recommend that calibration of new Vitalo- 
graph R models are performed at least every month 
until the rate of volume drift is established. For 
long-term trials, mechanical adjustment of the Vita- 
lograph will introduce an extra source of error and 
should probably not be done after each calibration. 
Instead, it is recommended that the necessary adjust- 
ments are made in the calculation of results. 
The results from spirometry in healthy volunteers 
(Table 3) showed different patterns. However, in all 
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Table 3 Variation in FEV, and FVC during home spirometry in 10 healthy volunteers 
Ten measurements 
within 2 h 
FEV, 
Daily measurements 
(BID) during 1 month 
Variation 
Subject 
Mean 
(1) 
Mean Diurnal Residual 
(1) (“W W) 
FVC 
Ten measurements 
within 2 h 
Daily measurements 
(BID) during 1 month 
Variation 
Mean 
(1) 
Mean Diurnal Residual 
(1) (“/I (“4 
1 5.09 2.5 4.98 -0.1 2.0 6.51 0.9 6.41 - 1.4 1.4 
2 4.01 0.9 3.99 0.5 1.9 4.61 1.2 4.67 - 0.3 2.5 
3 5.10 3.3 5.24 - 2.0 2.3 6.14 2.6 6.23 - 2.7 2.5 
4 3.70 1.6 3.63 - 1.6 1.9 4.46 0.9 4.48 -0.8 2.0 
5 5.48 2.1 5.38 - 4.8 2.4 6.53 2.6 6.36 - 5.9 2.6 
6 4.11 1.5 4.83 - 0.9 1.6 5.41 3.5 5.40 1.9 2.4 
I 3.05 2.4 2.91 0.1 4.2 3.52 3.3 3.47 2.5 5.7 
8 4.49 1.8 4.34 0.3 2.6 5.63 6.4 5.61 - 0.4 2.2 
9 4.53 0.7 4.47 - 1.9 2.2 5.65 0.8 5.71 - 1.9 1.8 
10 4.49 3.1 4.35 - 1.6 3.4 5.26 3.7 5.21 0.3 3.4 
Table 4 Variation in FEV, and FVC during home spirometry in 10 patients with 
a,-antitrypsin deficiency 
Subject 
Number of 
observations 
Mean 
(1) 
FEV, 
Variation 
Diurnal Residual 
(“!I (“4 
Mean 
0) 
FVC 
Variation 
Diurnal Residual 
WI (“4 
1 591 1.00 -0.1 5.9 1.82 2.2 4.9 
2 655 1.18 5.0 7.1 2.04 6.3 6.9 
3 923 1.48 6.9 7.2 3.54 5.2 6.2 
4 362 1.83 8.8 4.6 3.80 5.6 5.2 
5 649 2.32 10.1 5.6 5.28 2.3 4.2 
6 397 1.61 3.4 6.1 3-61 1.0 5.1 
7 456 2.25 9.8 4.2 4.03 8.5 4.1 
8 544 1.65 4.8 5.2 3.30 0.6 3.8 
9 456 1.10 - 0.8 5.5 4.70 0.4 3.3 
10 476 1.17 - 0.5 4.4 3.01 - 1.3 4.5 
cases the repeatability (3 x 10 measurements within FVC previously reported (15) has been taken into 
2 h) was better (smaller variation) for both FEV, and account by linear regression. Differences between 
FVC compared to daily measurements over 1 month. patients are obvious and as shown in Table 4, several 
Nevertheless, the variation of FEV, and FVC meas- patients showed diurnal variation in ventilatory 
ured at home was of the same size as reported from capacity of a magnitude which has not previously 
respiratory laboratories (27) (Table 3). been reported in PiZ patients. 
The patients with emphysema showed a high 
degree of motivation for performing PASS (Tables 3, 
4), and during a 2 yr observation period, a decline in 
ventilatory capacity was to be expected. Although 
this change was partly antagonized by the observed 
drift in volume registration, the total variation of 
results was probably increased by these factors. In 
Table 4, the time-dependent decline in FEV, and 
At present, the scope of PASS is not known. Today 
there is no doubt that small, pocket-sized spirom- 
eters, with data storage capacity, can be used for 
PASS, but further standardization is still necessary. It 
has previously been demonstrated that PASS can be 
performed in highly selected groups of patients 
(12,13), but the quality of the expiratory manoeuvres 
which are critical (16) for the quality of spirometry 
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were unknown until recently (14). This study shows 
that the results obtained by Finkelstein et al. (14), 
who used an advanced system for telephone transmit- 
ted, on-line supervision of the patients, can be 
obtained with the same reliability and reproducibility 
using technically simple equipment and monthly 
supervision of the patients. From these results, it is 
clear that a new range of studies in respiratory 
medicine will be possible (2%30), but before PASS is 
used extensively, as new, low price, pocket-sized 
spirometers are launched, it should be stressed 
that methods and equipment should be tested and 
standardized in the same way as equipment for 
laboratory use (3,8-10,17). Therefore, clinical studies 
based on PASS should either use a well-documented 
protocol or include an internal quality assurance 
programme. 
Conclusion 
Patient-administered sequential spirometry can be 
done without loss of reliability and reproducibility 
compared to laboratory spirometry. After adequate 
instructions and training, well-motivated patients can 
learn to perform daily self-administered spirometry 
(PASS) with correct expiratory technique. With 
monthly supervision of patient performance, this new 
concept may pave the way for a wide range of clinical 
studies which were considered impossible until 
recently (29,30). 
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